Literature DB >> 15467975

High dose antipsychotic use in schizophrenia: findings of the REAP (research on east Asia psychotropic prescriptions) study.

K Sim1, A Su, J Y Leong, K Yip, M Y Chong, S Fujii, S Yang, G S Ungvari, T Si, E K Chung, H Y Tsang, N Shinfuku, E H Kua, C H Tan.   

Abstract

BACKGROUND: High-dose antipsychotic regimes (defined as the prescription of more than 1000 chlorpromazine-equivalents milligrams of antipsychotic per day) in the management of patients with schizophrenia are not uncommon, but most reports are from western countries. Recent functional neuroimaging studies have found that the previous notion concerning the use of antipsychotic medication, especially in high doses, was unsupported and untenable.
METHODS: This international study examined the use of high dose antipsychotic medication and its clinical correlates in schizophrenia patients within six East Asian countries/territories.
RESULTS: Within the study group (n = 2399), 430 patients (17.9%) were prescribed high dose antipsychotics. Antipsychotic use varied significantly between countries, with Japan, Korea, and Singapore using higher doses than the other countries. High dose antipsychotic use was associated with younger age in Japan (p < 0.001), longer duration of admission (p < 0.001), duration of illness (p < 0.001, particularly in Korea and Taiwan), positive psychotic symptoms (p < 0.001, particularly in Japan and Korea), and aggression (p < 0.05, particularly in Japan), and also with a higher likelihood of extrapyramidal and autonomic adverse effects (p < 0.05, particularly in China). Country, younger age, the presence of delusions and disorganized speech, polypharmacy, and receiving depot medication but not atypical antipsychotic drugs were important predictors of high antipsychotic use.
CONCLUSIONS: This survey revealed that high antipsychotic dosing is not an uncommon practice in East Asia. It behooves the prescribing clinicians to constantly reevaluate the rationale for such a practice.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15467975     DOI: 10.1055/s-2004-827174

Source DB:  PubMed          Journal:  Pharmacopsychiatry        ISSN: 0176-3679            Impact factor:   5.788


  14 in total

1.  Attitudes toward taking medication among outpatients with schizophrenia: cross-national comparison between Tokyo and Beijing.

Authors:  Naoaki Kuroda; Shiyou Sun; Chih-Kuang Lin; Nobuaki Morita; Hirotaka Kashiwase; Fude Yang; Yoji Nakatani
Journal:  Environ Health Prev Med       Date:  2008-08-12       Impact factor: 3.674

2.  Prevalence and correlates of insomnia and its impact on quality of life in Chinese schizophrenia patients.

Authors:  Yu-Tao Xiang; Yong-Zhen Weng; Chi-Ming Leung; Wai-Kwong Tang; Kelly Y C Lai; Gabor S Ungvari
Journal:  Sleep       Date:  2009-01       Impact factor: 5.849

3.  High-dose antipsychotic use in schizophrenia: a comparison between the 2001 and 2004 Research on East Asia Psychotropic Prescription (REAP) studies.

Authors:  Kang Sim; Hsin Chuan Su; Senta Fujii; Shu-Yu Yang; Mian-Yoon Chong; Gabor Ungvari; Tianmei Si; Yan Ling He; Eun Kee Chung; Yiong Huak Chan; Naotaka Shinfuku; Ee Heok Kua; Chay Hoon Tan; Norman Sartorius
Journal:  Br J Clin Pharmacol       Date:  2009-01       Impact factor: 4.335

Review 4.  Conceptual and methodological issues in the design of clinical trials of antipsychotics for the treatment of schizophrenia.

Authors:  William G Honer; Allen E Thornton; Megan Sherwood; G William MacEwan; Tom S Ehmann; Richard Williams; Lili C Kopala; Ric Procyshyn; Alasdair M Barr
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

5.  Reducing antipsychotic polypharmacy among psychogeriatric and adult patients with chronic schizophrenia.

Authors:  Yen-Li Goh; Kok Han Seng; Alex Su Hsin Chuan; Hong Choon Chua
Journal:  Perm J       Date:  2011

6.  Development of a Web-Based Clinical Decision Support System for Drug Prescription: Non-Interventional Naturalistic Description of the Antipsychotic Prescription Patterns in 4345 Outpatients and Future Applications.

Authors:  Sofian Berrouiguet; Maria Luisa Barrigón; Sara A Brandt; Santiago Ovejero-García; Raquel Álvarez-García; Juan Jose Carballo; Philippe Lenca; Philippe Courtet; Enrique Baca-García
Journal:  PLoS One       Date:  2016-10-20       Impact factor: 3.240

Review 7.  Long-acting antipsychotic drugs for the treatment of schizophrenia: use in daily practice from naturalistic observations.

Authors:  Giuseppe Rossi; Sonia Frediani; Roberta Rossi; Andrea Rossi
Journal:  BMC Psychiatry       Date:  2012-08-21       Impact factor: 3.630

8.  Effective therapeutic dosage of antipsychotic medications in patients with psychotic symptoms: Is there a racial difference?

Authors:  Muideen O Bakare
Journal:  BMC Res Notes       Date:  2008-06-12

9.  Study protocol: safety correction of high dose antipsychotic polypharmacy in Japan.

Authors:  Tsuruhei Sukegawa; Ataru Inagaki; Yoshio Yamanouchi; Toshiya Inada; Takashi Yoshio; Reiji Yoshimura; Nakao Iwata
Journal:  BMC Psychiatry       Date:  2014-04-07       Impact factor: 3.630

10.  Differences in High Dose Antipsychotic Prescriptions in Patients with Schizophrenia in Asian Countries/Areas: Findings from the REAP-AP Study.

Authors:  Yong Chon Park; Shu-Yu Yang; Mian-Yoon Chong; Shigenobu Kanba; Norman Sartorius; Naotaka Shinfuku; Chay-Hoon Tan; Seon-Cheol Park
Journal:  Psychiatry Investig       Date:  2018-10-22       Impact factor: 2.505

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.